Tevogen Bio, a clinical stage biotechnology company, has submitted its Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for the development of COVID-19 treatment using proprietary antigen specific T cell technology, it was reported on Wednesday.
The company is collaborating with bone marrow transplant expert, Dr Neal Flomenberg, chair of the Department of Medical Oncology at Thomas Jefferson University, with the aim of assessing the company's T cell technology to treat hospitalised COVID-19 patients.
The partnership intends to use Tevogen's proprietary immunotherapy platform and Dr Flomenberg's expertise in research and the transplantation of T cells so that both can conduct clinical trials of T cell treatments for COVID-19. In the proposed trials, T cells will be generated in the laboratory and administered to those patients in the COVID-19 spectrum that are most ill.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients